Pengaruh Modifikasi Pola Hidup Medis Dengan Atau Tanpa Metformin Terhadap Kadar Asymmetrical Dimethyl Arginine (ADMA) Pada Penderita Obesitas

1.

Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged
Subcutaneous Abdominal Adipocyte Size, But Not Obesity Itself, Predicts type
II Diabetes Independent of Insulin Resistance. Diabetologia. 43, 1498-1506

2.

Hossain P, Kawar B. Obesity and Diabetes in developing world: a growing
Chalengge. In : N Engl J Med; 2007; 356:213-15

3.

Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM.
Prevalence of overweight and obesity in the United Stated, 1999-2004. JAMA;
2006; 295 (13): 1549-1555

4.

Obesitas, Faktor Resiko Berbagai Penyakit. Anda Obesitas?, Awas Bahaya
Mengancam!.

Diakses

26

Februari

2014.

Tersedia

dari

http://www.dinkes.jogjaprov.go.id
5.

Sugondo S. Obesitas. Dalam : Buku Ajar Ilmu Penyakit Dalam. Sudoyo AW,
Setiyohadi B, Alwi I, dkk (Eds). Jakarta. Pusat Penerbitan Ilmu Penyakit Dalam
FKUI; 2009; 5;3:1973-83

6.

Survey Penyakit Degeneratif di Medan. Laporan Penelitian Kerjasama Subdin
Yankes dan Rujukan Din Kes Prop Sumut dengan Departemen IKM/KP/IKK
FK USU

7.

Misra A, Khurana L. Obesity and the Metabolic Syndrome in Developing
Countries. J. Clin. Endocrinol. Metab; 2008 93: s9-s30

8.

Adams KF, Schatzkin A, Harris TB, Kipnis B, Mouw T, Ballard-Barbash R et
al. Overweight, obesity and mortality in a alarge prospective cohort of persons
50 to 71 years old. N Engl J Med;2000; 355, 763-778

9.

Bray. Medical Consequence of Obesitasity. In: J Clin Endocrinol Metab;

2004;89(6):2583-9

10.

Roberts MJ, Bodnar LM, Patrick TE, Powers RW. The Role of Obesity in
PreeclampsiaPregnancy Hypertens. 2011 January 1; 1(1): 6–16

11.

Koc F, Tokac M, Erdem S, Kaya C, Unlu A, Karabag T, et al. Serum
asymmetric dimethylarginine levels in normotensive obese individuals. Med Sci
Monit, 2010; 16(11): CR536-539

12.

Schernthaner G. ADMA, cardiovascular disease, and diabetes. 2008

13.

Jan T. Kielstein, Cooke JP. Should We Measure Asymmetric Dimethylarginine

in Patients with Coronary Artery Disease?, Clinical Chemistry 2007;53:161-163

Universitas Sumatera Utara

14.

Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M , Adegoke OAJ,
et al.Elevations of plasma methylarginines in obesity and ageing are related to
insulin sensitivity and rates of protein turnover. Diabetologia (2006) 49: 351–
359

15.

Molitch ME, Fujimoto W, Hammon RF, Knowler WC. The diabetes prevention
program and its global implications. In: J Am Soc Nephrol; 2003;14:103-7

16.

Ulf G, Bronas. Alternative Forms of Exercise Training Complementary Therapy
in the Prevention and Management of Type 2 Diabetes. Diabetes Spectrum

September 21, 2009 vol. 22 no. 4 220-225

17.

Sugondo S. Obesitas pada Sindroma Metabolik: Penyebab atau akibat. Dalam:
Naskah lengkap PIT Penyakit Dalam 2005. Jakarta. Pusat Penerbitan Ilmu
Penyakit Dalam FKUI; 2005: 83-6

18.

Sumiardji G. Prediabetes: Apakah perlu diobati?. Dalam: Naskah Lengkap PIT
Ilmu Penyakit Dalam FK USU 2006. Medan; 2006: 113-5

19.

Bestermann WH Jr. The ADMA-Metformin Hypothesis: Linking the
Cardiovascular Consequences of the Metabolic Syndrome and Type 2 Diabetes.
Cardiorenal Med 2011;1:211–219

20.

Landim MBP, Filho AC, Chagas ACP. Asymmetric dimethylarginine(ADMA)
and endothelial dysfunction: implications for atherogenesis,

CLINICS

2009;64(5):471-8
21.

Despres JP. Potensial contribution of metformin to management of
cardiovascular disease risk in patients with abdominal obesity, the metabolic
syndrome and type 2 diabetes. In: Diabetes Metab; 2003; 29:6S53-61

22.

Vallance

P,

Leiper

J.

Cardiovascular

Dimethylarginine:Dimethylarginine

Biology

of

the

Dimethylaminohydrolase

Asymmetric
Pathway

Arterioscler Thromb Vasc Biol 2004;24;1023-1030
23.

Maeda S, Miyaki A, Kumagai H, Eto M, So R, Tanaka K, et al. Lifestyle
modification

decreases

arterial

stiffness

and

plasma

asymmetric

dimethylarginine level in overweight and obese men. Coronary Artery Disease
2013; 24: 583-88

Universitas Sumatera Utara

24.

Sibal L, Agarwal1 SC, Home PD, Boger RH. The Role of Asymmetric
Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular
Disease Current Cardiology Reviews, 2010, 6, 82-90

25.

Hariawan KN, Suastika K. Hubungan Kendali Glikemik dengan Asymmetric
Dimethylarginine Penderita Diabetes Melitus Tipe 2 Lanjut Usia. Jurnal
Penyakit Dalam 2008;9:203-214

26.

Palm F, Onozato

ML, Luo Z, Wilcox

CS.

Dimethylarginine

dimethylaminohydrolase (DDAH): expression, regulation, and function in the
cardiovascular and renal systems. American Journal of Physiology - Heart and
Circulatory Physiology 2007;293: H3227-H3245
27.

Bo¨ger RH. The Emerging Role of Asymmetric Dimethylarginine as a
NovelCardiovascular Risk Factor. Cardiovascular Research 2003;59: 824–833

28.

Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I. Relationship between
obesity, smoking, and the endogenous nitric oxide synthase inhibitor,
asymmetric dimethylarginine.Metabolism 2004; 53:1574–1579

29.

Spoto B, Parlonqo RM, Parlonqo G, Sqro E, Zoccali C. The Enzymatic

machinery for ADMA synthesis and degradation is fully expressed in human
adipocytes. J Nephrol 2007; 20(5): 554-559

30.

Krzyzanowska K, Mittermayer F, Kopp HP, Wolzt M, Schernthaner G. Weight
Loss Reduces Circulating Asymmetrical Dimethylarginine Concentrations In
Morbidly Obese Women. J Clin. Endocrinol. Metab. 2004;89 ( 12): 6277-6281

31.

Heutling D, Schulz H, Nickel I, Kleinstein J, Kaltwasser P, Westphal S et al.
Asymmetrical Dimethylarginine, Inflammatory and Metabolic Parameters in
Women with Polycystic Ovary Syndrome before and after Metformin
Treatment. J. Clin. Endocrinol. Metab. 2008; 93:82-90

32.

Tirtawinata TC. Obesitas dan permasalahannya, dalam Ingin Menjadi Langsing?
Penanggulangan Obesitas Secara Terpadu. Jakarta. Badan Penerbit FK UI; 2012:
2

33.

Madani R. Signals from adipose tissue in morbid obesity and effect on depot
specific

differences.University

College

London.

2009.

Tersedia

dari

http://discovery.ucl.ac.uk/18917/1/18917.pdf

Universitas Sumatera Utara

34.

World Health Consultation on Obesity. World Health Organization : Technical
Report Serries No. 894 : Obesity ; Preventing and Managing the Global
Epidemic.WHO.2000

35.

The National Institute of Health. Clinical Guideline on identification, evaluation
and the treatment of overweight and obesity in adult.Obes.Res 1998;6:51S

36.

Schwart MW, Porte JR. Diabetes, Obesity, and the brain. Science;
2005.307(5708):375-9

37.

Jousilahti P, Tuomilehto J, Vartiainen E, Pekkanen J, Puska P.Body weight,
cardiovascular risk factors, and coronary mortality. 15-year follow-up of middleaged men and women in eastern Finland. Circulation. 1996;93:1372-1329

38.

Desilet RA, Karki SD, Dunican KC. Role of Metformin for weight management
in Patients without type 2 diabetes mellitus. In: The Annual of Pharmacotherapy;
2008; 42:817-27

39.

Zhang JL, Zheng X, Zou DJ, Qiu JL, Zhao XX, Qin YW. Effect of metformin
on weight gain during antihypertensive treatment with a beta blocker in Chinese
patients. Am.J.Hypertense. 2009; 22 (8): 884-90

40.

Madiyono B, Sastroasmoro S, Ismael S. Perkiraan Besar Sampel dalam Dasardasar Metodologi Penelitian Klinis. Jakarta : Sagung Seto 2008;3;16: 302-330

41.

PERKENI. Konsensus Pengelolaan Diabetes Melitus Tipe 2 di Indonesia;
Jakarta ; 2006

42.

Markus A. Neurobiology of Obesitasity. Nat Neurosci.2005;8(5):551

43.

Obesity

and

overweight

Accessed:

20th

May,

2013

tersedia

dari:

http://www.who.int/mediacentre/factsheets/fs311/en/
44.

Jensen MD, Ryan DH, Apovian CM, Ard DJ, Comuzzie GA, Donato KA et al.
2013 AHA/ACC/TOS Guideline for the Management of Overweight and
Obesity in Adults: A Report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines and The Obesity Society.
Circulation. 2013;00:000–000

45.

Levri KM, Slaymaker E, Last A, Yeh J, Ference J, D’Amico F.Metformin as
Treatment for Overweight and Obese Adults: A Systematic Review. Ann Fam
Med 2005;3:457-461

Universitas Sumatera Utara

46.

National Institute of Health. The Practical Guide Identification, Evaluation and
Treatment of Overweight and Obesity in Adults. 2000

47.

National Obesity Observatory.Treating adult obesity through lifestyle change
interventions, A briefing paper for commissioners. NHS 2010

48.

Manaf A. Effect of Metformin Therapy on Plasma Adiponectin in Obesity with
Prediabetes Patient; Laporan Penelitian; 2008

49.

Lee A, Morley JE. Metformin Decreases Food Consumption and Induces
Weight Loss in Subjects with Obesity Type II non Insulin Dependent Diabetes.
Obes Res ;1998; 6: 47-53

50.

Tankova T, Dakovska L, Kirilov G, Koev D. Metformin in The Treatment of
Obesity in Subjects With Normal Glucose Tolerance. Rom J Intern 2003; 41:
269-75

51.

Glueck CJ, Fontaine RN, Wang P, Subbiah MT, Weber K, Illig E et al.
Metformin Reduces Weight, Centripetal Obesity, Insulin, Leptin and Low
Density Lipoprotein Cholesterol in non diabetic, morbidly obese subjects With
Body Mass Index Greater Than 30. Metabolism 2001; 50, 856-861

52.

Taskiran B, Altun BU, Vardar SA, Demir AM, Karadag CH, Altun A. Effect of
Exercise on ADMA Level in Type 2 Diabetes MellitusBalkan Med J 2012; 29:
62-7

53.

Gomes VA, Casella-Filho A, Chagas ACP, Tanus-Santos JE. Enhanced
concentrations of relevant markers of nitric oxide formation after exercise
training in patients with metabolic syndrome.Nitric Oxide 2008;19:345-50

54.

Asagami T, Abbasi F, Stuelinger M, Lamendola C, McLaughlin T, Cooke JP et
al..Metformin Treatment Lowers Asymmetric Dimethylarginine Concentrations
in Patients With Type 2 Diabetes. Metabolism, Vol 51, No 7 (July), 2002: pp
843-846

55.

Mclaughlin T, Stuhlinger M, Lamendola C, Abbasi F, Bialek J, Reaven G et al.
Plasma Asymemetric Dimethylarginine Concentrations Are Elevated in Obese
Insulin Resistant Women and Fall with Weight Loss. J Clin Endocrinol Metab;
2006; 91: 1896-1900

Universitas Sumatera Utara